Bayer's new gynaecological drug, Visanne, has been approved by Chinese regulators to treat endometriosis

, Germany'spharmaceutical(http://giant Bayer announced that, the http:// new drug in theof gynaecology,, was approved by Chinese regulators for the treatment of endometriosis (EMs)VisanneVisanne is a daily oral tablet containing 2 mg of dinopronocet , which is designed to treat EMs, a chronic gynaecological diseaseVisanne is a new selective progesterone receptor agonist that inhibits ovarian function and the proliferation of endometrial cells, thereby reducing the pain associated with EMs and reducing and atrophyMany international clinical studieshave shown that Visanne can effectively relieve EMs pain, reduce endometriosis, and have good safety and toleranceIn addition to China, Visanne has been approved by more than 70 countries around the worldVisanne is thecompany's(http://the approval of the product http://
in China in the past year previous approvals include: (1) In July this year, the new hemophilia drug Kovaltry (injecting recombinant coagulation factor VIII, brand name: KoJuqi) was approved for treatment of adults and children with type A haemophilia (routine prevention, on-demand treatment, management of perioperative haemorrhage http://
); Brand name: Alya) approved for the treatment of adult newborn vascular (wet) age-associated macular degeneration (nAMD); (3) in February this year, Eylea (Alia) approved for the treatment of adult diabetic macular edema (DME); (4) in December last year, targeted anti-cancer drug Stivarga (regofini, brand name: Bevango) approved, The approval for the treatment of patients with hepatocellular carcinoma (HCC) who have been treated with Soraphini marks a new breakthrough in the treatment of liver cancer in China over the past 10 years